

Bernard L Marini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7389820/publications.pdf>

Version: 2024-02-01

81
papers

949
citations

471509

17
h-index

526287

27
g-index

84
all docs

84
docs citations

84
times ranked

1889
citing authors

#	ARTICLE	IF	CITATIONS
1	Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 1797-1806.	1.3	65
2	Role of T Cell TGF β 2 Signaling and IL-17 in Allograft Acceptance and Fibrosis Associated with Chronic Rejection. <i>Journal of Immunology</i> , 2009, 183, 7297-7306.	0.8	59
3	Characterizing and targeting <i>PDGFRA</i> alterations in pediatric high-grade glioma. <i>Oncotarget</i> , 2016, 7, 65696-65706.	1.8	55
4	Serum posaconazole levels among haematological cancer patients taking extended release tablets is affected by body weight and diarrhoea: single centre retrospective analysis. <i>Mycoses</i> , 2015, 58, 432-436.	4.0	53
5	Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations. <i>Neuro-Oncology</i> , 2019, 21, 968-980.	1.2	52
6	Everolimus improves the efficacy of dasatinib in PDGFR \pm -driven glioma. <i>Journal of Clinical Investigation</i> , 2020, 130, 5313-5325.	8.2	41
7	Risk factors for subtherapeutic levels of posaconazole tablet. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2902-2905.	3.0	37
8	Catalyzing improvements in ALL therapy with asparaginase. <i>Blood Reviews</i> , 2017, 31, 328-338.	5.7	37
9	Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 141, 125-138.	4.4	36
10	Targeting and Therapeutic Monitoring of H3K27M-Mutant Glioma. <i>Current Oncology Reports</i> , 2020, 22, 19.	4.0	35
11	The leukemia strikes back: a review of pathogenesis and treatment of secondary AML. <i>Annals of Hematology</i> , 2019, 98, 541-559.	1.8	34
12	The effects of an informational video on patient knowledge, satisfaction and compliance with venous thromboembolism prophylaxis: A pilot study. <i>Patient Education and Counseling</i> , 2014, 96, 264-267.	2.2	29
13	Risk factors and impact of <i>Clostridium difficile</i> recurrence on haematology patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1488-1495.	3.0	28
14	A single-center multidisciplinary approach to managing the global Erwinia asparaginase shortage. <i>Leukemia and Lymphoma</i> , 2019, 60, 2854-2868.	1.3	25
15	Daptomycin nonsusceptible vancomycin resistant <i>Enterococcus</i> bloodstream infections in patients with hematological malignancies: risk factors and outcomes. <i>Leukemia and Lymphoma</i> , 2017, 58, 2852-2858.	1.3	20
16	The FOSSIL Study: FLAG or standard 7+3 induction therapy in secondary acute myeloid leukemia. <i>Leukemia Research</i> , 2018, 70, 91-96.	0.8	20
17	PEGging down risk factors for peg-asparaginase hepatotoxicity in patients with acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 617-624.	1.3	18
18	Maintenance sorafenib in FLT3-ITD AML following allogeneic HCT favorably impacts relapse and overall survival. <i>Bone Marrow Transplantation</i> , 2019, 54, 1518-1520.	2.4	18

#	ARTICLE	IF	CITATIONS
19	Development of the CNS TAP tool for the selection of precision medicine therapies in neuro-oncology. <i>Journal of Neuro-Oncology</i> , 2018, 137, 155-169.	2.9	15
20	Panobinostat penetrates the blood-brain barrier and achieves effective brain concentrations in a murine model. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 555-562.	2.3	15
21	A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia. <i>Journal of Oncology Pharmacy Practice</i> , 2018, 24, 453-467.	0.9	14
22	Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2020, 61, 691-698.	1.3	13
23	Blood-brain barrier-adapted precision medicine therapy for pediatric brain tumors. <i>Translational Research</i> , 2017, 188, 27.e1-27.e14.	5.0	12
24	Rational use of rasburicase for the treatment and management of tumor lysis syndrome. <i>Journal of Oncology Pharmacy Practice</i> , 2018, 24, 176-184.	0.9	12
25	Incidence and Risk Factors for Breakthrough Invasive Mold Infections in Acute Myeloid Leukemia Patients Receiving Remission Induction Chemotherapy. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz176.	0.9	12
26	Clinically Integrated Sequencing Alters Therapy in Children and Young Adults With High-Risk Glial Brain Tumors. <i>JCO Precision Oncology</i> , 2018, 2, 1-34.	3.0	10
27	Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 2184-2192.	1.3	10
28	Early Antibiotic Discontinuation or De-escalation in High-Risk Patients With AML With Febrile Neutropenia and Prolonged Neutropenia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 245-252.	4.9	10
29	Identification and targeting of an FGFR fusion in a pediatric thalamic central oligodendroglioma. <i>Npj Precision Oncology</i> , 2017, 1, 29.	5.4	9
30	Impact of antibacterial prophylaxis during reinduction chemotherapy for relapse/refractory acute myeloid leukemia. <i>Supportive Care in Cancer</i> , 2017, 25, 541-547.	2.2	9
31	Successful reintroduction of blinatumomab in a patient with relapsed/refractory acute lymphoblastic leukemia following grade 4 cytokine release syndrome. <i>Journal of Oncology Pharmacy Practice</i> , 2018, 24, 67-73.	0.9	9
32	Comparative pharmacokinetic analysis of the blood-brain barrier penetration of dasatinib and ponatinib in mice. <i>Leukemia and Lymphoma</i> , 2021, 62, 1990-1994.	1.3	9
33	Intrathecal alemtuzumab: a potential treatment of refractory leptomeningeal T-cell prolymphocytic leukemia. <i>Blood Advances</i> , 2019, 3, 3333-3336.	5.2	8
34	Pharmacokinetic and clinical considerations for monitoring asparaginase activity levels during pegaspargase therapy. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1115-1115.	1.5	7
35	Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG. <i>Annals of Hematology</i> , 2018, 97, 573-584.	1.8	7
36	Managing liver dysfunction in haematology patients: Switch antifungals, or use the tincture of time?. <i>Mycoses</i> , 2019, 62, 214-216.	4.0	7

#	ARTICLE	IF	CITATIONS
37	Risk factors for piperacillin/tazobactam-resistant Gram-negative infection in hematology/oncology patients with febrile neutropenia. <i>Supportive Care in Cancer</i> , 2015, 23, 2287-2295.	2.2	6
38	Successful use of high-dose cytarabine in a patient with acute myeloid leukemia and severe hepatic dysfunction. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 811-815.	0.9	5
39	Predictors for requiring re-induction chemotherapy in acute myeloid leukemia patients with residual disease on day 14 bone marrow assessment. <i>Leukemia Research</i> , 2017, 63, 56-61.	0.8	5
40	Successful use of cytarabine and bendamustine in a patient with mantle cell lymphoma and acute renal failure using intermittent hemodialysis: A case report. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 731-734.	0.9	5
41	Expanding the armamentarium for chronic lymphocytic leukemia: A review of novel agents in the management of chronic lymphocytic leukemia. <i>Journal of Oncology Pharmacy Practice</i> , 2017, 23, 502-517.	0.9	4
42	Impact of prophylactic intrathecal chemotherapy on CNS relapse rates in AML patients presenting with hyperleukocytosis. <i>Leukemia and Lymphoma</i> , 2020, 61, 862-868.	1.3	4
43	Impact of high dose cytarabine dosing strategies in obese patients with acute myeloid leukemia. <i>Leukemia Research</i> , 2021, 102, 106517.	0.8	4
44	Hybrid chemotherapy regimen (FLAG-IDA-vincristine-prednisone) for acute leukemia with mixed-phenotype blasts. <i>Leukemia Research</i> , 2021, 103, 106539.	0.8	4
45	Utility of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) nasal screening in patients with acute myeloid leukemia (AML). <i>Transplant Infectious Disease</i> , 2021, 23, e13612.	1.7	4
46	Risk for Invasive Fungal Infections during Acute Myeloid Leukemia Induction Therapy: a True Association with Echinocandins?. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4988-4989.	3.2	3
47	Risk of graft-versus-host disease with rituximab-containing conditioning regimens in allogeneic hematopoietic stem cell transplant. <i>Journal of Oncology Pharmacy Practice</i> , 2017, 23, 255-263.	0.9	3
48	Successful use of blinatumomab in a patient with acute lymphoblastic leukemia and severe hepatic dysfunction. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 200-205.	0.9	3
49	Lenalidomide Plus Hypomethylating Agent as a Treatment Option in Acute Myeloid Leukemia With Recurrent Genetic Abnormalities: AML With inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 24-30.	0.4	3
50	Impact of a vincristine dose cap on the incidence of neuropathies with DA-EPOCH-R for the treatment of aggressive lymphomas. <i>Leukemia and Lymphoma</i> , 2020, 61, 1126-1132.	1.3	3
51	Oral Azacitidine Maintenance for Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2021, 384, e51.	27.0	3
52	Therapeutic Outcomes of Patients with Acute Erythroid Leukemia Treated with Hypomethylating Agents. <i>Blood</i> , 2016, 128, 5203-5203.	1.4	3
53	Novel approaches in the pharmacotherapy of skeletal-related events in metastatic castrate-resistant prostate cancer. <i>Anticancer Research</i> , 2012, 32, 2391-8.	1.1	3
54	Minimizing waste during preparation of blinatumomab infusions. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 19-20.	1.0	2

#	ARTICLE	IF	CITATIONS
55	Pegasparaginase silent inactivation during therapy for NK/T cell lymphoma. <i>Leukemia and Lymphoma</i> , 2018, 59, 1596-1605.	1.3	2
56	PDCT-12. CLINICAL EFFICACY OF ONC201 IN THALAMIC H3 K27M-MUTANT GLIOMA. <i>Neuro-Oncology</i> , 2019, 21, vi186-vi186.	1.2	2
57	Role of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1695-1702.	0.9	2
58	Contemporary treatment options for a classical disease: Advanced Hodgkin lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 148, 102897.	4.4	2
59	Real world use of FLT3 inhibitors for treatment of FLT3+ acute myeloid leukemia (AML): A single center, propensity-score matched, retrospective cohort study. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 1315-1325.	0.9	2
60	Late-onset complications with bendamustine versus CHOP or CVP based chemoimmunotherapy in indolent Non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-9.	1.3	2
61	Clinical Availability of ATRA for Patients With Suspected Acute Promyelocytic Leukemia: Why Guidelines May Not Be Followed. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, , .	4.9	2
62	Impact of number of lumens in central-venous catheters on central-line bloodstream infection (CLABSI) and venous thromboembolism (VTE) risk in patients with acute leukemia. <i>Infection Control and Hospital Epidemiology</i> , 2023, 44, 125-127.	1.8	2
63	Efficacy of HMA +/- Venetoclax or Intensive Chemotherapy in Blast-Phase Myeloproliferative Neoplasms. <i>Blood</i> , 2021, 138, 2569-2569.	1.4	2
64	Oncology stewardship in acute myeloid leukemia. <i>Annals of Hematology</i> , 2022, 101, 1627-1644.	1.8	2
65	Real-Life Challenges to the Use of Antifungal Agents in Hematology Patients. <i>Current Fungal Infection Reports</i> , 2017, 11, 229-241.	2.6	1
66	Mini-CHCVD plus inotuzumab plus or minus blinatumomab: Hype or hope?. <i>Cancer</i> , 2019, 125, 3890-3891.	4.1	1
67	PET-guided, BEACOPP-escalated therapy in advanced Hodgkin lymphoma. <i>Lancet Oncology</i> , The, 2019, 20, e188.	10.7	1
68	Propensity-score Matched Comparison of Salvage Chemotherapy Regimens in Relapsed/Refractory Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 393-400.e1.	0.4	1
69	Identification of variant APL translocations PRKAR1A-RAR α and ZBTB16-RAR α (PLZF-RAR α) through the MI-ONCOSEQ platform. <i>Cancer Genetics</i> , 2021, 258-259, 57-60.	0.4	1
70	Multi-Center Retrospective Evaluation of High-Dose Cytarabine Based Induction Versus CPX-351 Induction in Patients with Secondary AML. <i>Blood</i> , 2019, 134, 2639-2639.	1.4	1
71	The effect of everolimus on CNS penetration and efficacy of dasatinib in the treatment of PDGFRA-driven glioma.. <i>Journal of Clinical Oncology</i> , 2019, 37, e13508-e13508.	1.6	1
72	Multicenter comparison of first salvage chemotherapy versus novel therapy regimens in adult relapsed/refractory acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2022, 63, 1839-1848.	1.3	1

#	ARTICLE	IF	CITATIONS
73	Expanding Access to CNS-TAP: Design, Development, and Initial Use of a Complex Precision Health Specialty Web App for Neuro-Oncology. <i>Studies in Health Technology and Informatics</i> , 2022, , .	0.3	1
74	“VTE and You”: Assessment of a VTE Patient Education Video (InPHARMmercial) and an Electronic Risk Scoring Tool in Hospitalized Medicine Patients. <i>Chest</i> , 2011, 140, 592A.	0.8	0
75	HGG-03. EVEROLIMUS TREATMENT IMPROVES THE CNS PENETRATION AND EFFICACY OF DASATINIB IN THE TREATMENT OF PDGFRA-DRIVEN PEDIATRIC HIGH-GRADE GLIOMA AND DIFFUSE INTRINSIC PONTINE GLIOMA. <i>Neuro-Oncology</i> , 2019, 21, ii87-ii87.	1.2	0
76	Evaluating the Role of Novel Oncology Agents: Oncology Stewardship in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 295-308.	0.4	0
77	EPCT-02. COMPARISON OF TARGETED AGENTS RECOMMENDED BY THE CNS-TAP TOOL TO THOSE SELECTED BY A TUMOR BOARD IN A MOLECULARLY-DRIVEN DIPG CLINICAL TRIAL. <i>Neuro-Oncology</i> , 2021, 23, i46-i46.	1.2	0
78	Lenalidomide Plus Hypomethylating Agent for Acute Myeloid Leukemia (AML) with Recurrent Genetic Abnormalities -AML with Inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, Mecom. <i>Blood</i> , 2018, 132, 4042-4042.	1.4	0
79	Real-World Outcomes with Immunosuppressive Therapy for Aplastic Anemia in Patients Treated at the University of Michigan. <i>Blood</i> , 2021, 138, 1126-1126.	1.4	0
80	Hard-wired biases in trials: maintenance azacitidine in patients with acute myeloid leukemia and framework for future trials. <i>Blood Advances</i> , 2022, , .	5.2	0
81	Predicting CNS penetration of precision medicine therapies in oncology: A comparison of the CNS TAP tool and the BOILED-Egg computational model.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2062-2062.	1.6	0